Abstract
Ischemic heart disease is the principal etiology of heart failure in the Western world. Myocardial ischemia is important in cardiac remodeling, a process that leads to a progressive change in the shape and size of the heart and significantly worsens the prognosis of patients with heart failure. Preventing ischemic events, therefore, is an important goal in the management of patients with coronary artery disease. Statins have been shown to reduce the number of ischemic events in these patients, whereas the benefit of beta‐blocker and aldosterone antagonist therapy on ischemic causes of heart failure remains unclear. Several large trials involving patients with asymptomatic left ventricular dysfunction after myocardial infarction or heart failure have shown that angiotensin‐converting enzyme (ACE) inhibitors reduce the incidence of progressive heart failure, death, and ischemic events, thus establishing ACE inhibitors as first‐line therapy for these patients. Other lines of evidence have suggested that ACE inhibitor therapy may also benefit patients with preserved left ventricular function, a hypothesis that is being evaluated in three large, controlled, randomized trials. One of these trials, the Heart Outcomes Prevention Evaluation (HOPE) study, was terminated prematurely because it demonstrated the significant positive effects of the ACE inhibitor ramipril on cardiovascular outcomes in patients with coronary artery disease and preserved left ventricular function. A growing body of data confirms the relationship between ischemia and heart failure and the benefits of ACE inhibitor treatment in a broad range of high‐risk patients.
Keywords: coronary artery disease, angiotensin‐converting enzyme inhibitor, left ventricular function, HOPE study, cardiac injury, myocardial infarction
Full Text
The Full Text of this article is available as a PDF (616.3 KB).
References
- 1. The SOLVD Investigators : Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685–691 [DOI] [PubMed] [Google Scholar]
- 2. The SOLVD Investigators : Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302 [DOI] [PubMed] [Google Scholar]
- 3. CIBIS Investigators and Committees : A randomized trial of p‐blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90: 1765–1773 [DOI] [PubMed] [Google Scholar]
- 4. Bart BA, Ertl G, Held P, Kuch J, Maggioni AP, McMurray J, Michelson EL, Rouleau JL, Stevenson LW, Swedberg K, Young JB, Yusuf S, Sellers MA, Granger CB, Califf RM, Pfeffer MA, for the SPICE investigators : Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur Heart J 1999; 20: 1182–1190 [DOI] [PubMed] [Google Scholar]
- 5. Eriksson H, Svardsudd K, Caidahl K, Bjuro T, Larsson B, Welin L, Ohlson LO, Wilhelmsen L: Early heart failure in the population. The study of men born in 1913. Acta Med Scand 1988; 223: 197–209 [DOI] [PubMed] [Google Scholar]
- 6. Parameshwar J, Shackell MM, Richardson A, Poole‐Wilson PA, Sutton GC: Prevalence of heart failure in three general practices in north west London. Br J Gen Pract 1992; 42: 287–289 [PMC free article] [PubMed] [Google Scholar]
- 7. Remes J, Reunanen A, Aromaa A, Pyorala K: Incidence of heart failure in eastern Finland: A population‐based surveillance study. Eur Heart J 1992; 13: 588–593 [DOI] [PubMed] [Google Scholar]
- 8. Zannad F, Briancon S, Julliere Y, Mertes PM, Villemot JP, Alla F, Virion JM, and the EPICAL investigators : Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: The EPICAL study. J Am Coll Cardiol 1999; 33: 734–742 [DOI] [PubMed] [Google Scholar]
- 9. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, Benedict C, Rousseau M, Bourassa M, Pitt B: Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340: 1173–1178 [DOI] [PubMed] [Google Scholar]
- 10. St. John Sutton M, Pfeffer MA, Moyé L, Plappert T, Rouleau JL, Lamas G, Rouleau J, Parker JO, Arnold MO, Sussex B, Braunwald E, for the SAVE investigators : Cardiovascular death and left ventricular remodeling two years after myocardial infarction: Baseline predictors and impact of long‐term use of captopril: Information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation 1997; 96: 3294–3299 [DOI] [PubMed] [Google Scholar]
- 11. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group : Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–1307 [DOI] [PubMed] [Google Scholar]
- 12. Scandinavian Simvastatin Survival Study Group : Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389 [PubMed] [Google Scholar]
- 13. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AMJ, for the AFCAPS/TexCAPS Research Group : Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. J Am Med Assoc 1998; 279: 1615–1622 [DOI] [PubMed] [Google Scholar]
- 14. Sacks FM, Pfeffer MA, Moyé LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators : The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001–1009 [DOI] [PubMed] [Google Scholar]
- 15. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LS, for the Atorvastatin versus Revascularization Treatment Investigators : Aggressive lipid‐lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999; 341: 70–76 [DOI] [PubMed] [Google Scholar]
- 16. Hashimoto M, Okamoto M, Yamagata T, Yamane T, Watanabe M, Tsuchioka Y, Matsuura H, Kajiyama G: Abnormal systolic blood pressure response during exercise recovery in patients with angina pectoris. J Am Coll Cardiol 1993; 22: 659–664 [DOI] [PubMed] [Google Scholar]
- 17. Packer M, Cohn JN, Eds., on behalf of the Steering Committee and Membership of the Advisory Council to Improve Outcomes Nationwide in Heart Failure: Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999; 83 (suppl): 1A–38A [PubMed] [Google Scholar]
- 18. Task Force of the Working Group on Heart Failure of the European Society of Cardiology : The treatment of heart failure. Eur Heart J 1997; 18: 736–753 [DOI] [PubMed] [Google Scholar]
- 19. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, Tsuyuki RT, White M, Rouleau J, Latini R, Maggioni A, Young J, Pogue J, for the RESOLVD Pilot Study Investigators : Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation 1999; 100: 1056–1064 [DOI] [PubMed] [Google Scholar]
- 20. CIBIS II Investigators and Committees : The Cardiac Insufficiency Bisoprolol Study (CIBIS II): A randomised trial. Lancet 1999; 353: 9–13 [PubMed] [Google Scholar]
- 21. Weber KT, Villarreal D: Aldosterone and antialdosterone therapy in congestive heart failure. Am J Cardiol 1993; 71 (suppl): 3A–l1A [DOI] [PubMed] [Google Scholar]
- 22. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD: Effects of adding spironolactone to an angiotensin‐converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995; 76: 1259–1265 [DOI] [PubMed] [Google Scholar]
- 23. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CJ: Mineralcorticoid blockade reduces vascular injury in stroke‐prone hypertensive rats. Hypertension 1998; 31: 451–458 [DOI] [PubMed] [Google Scholar]
- 24. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J, for the Randomized Aldactone Evaluation Study Investigators : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709–717 [DOI] [PubMed] [Google Scholar]
- 25. Garg G, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials : Overview of randomized trials of angiotensin‐converting enzyme inhibitors on mortality and morbidity in patients with heart failure. J Am Med Assoc 1995; 273: 1450–1456 [PubMed] [Google Scholar]
- 26. The Fourth International Study of Infarct Survival (ISIS‐4) Collaborative Group : ISIS‐4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669–685 [PubMed] [Google Scholar]
- 27. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico : GISSI‐3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6‐week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115–1122 [PubMed] [Google Scholar]
- 28. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators : Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821–828 [PubMed] [Google Scholar]
- 29. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EG Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM, for the SAVE Investigators : Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327: 669–677 [DOI] [PubMed] [Google Scholar]
- 30. Køber L, Torp‐Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC, Aliot E, Persson S, Camm AJ, for the Trandolapril Cardiac Evaluation (TRACE) Study Group : A clinical trial of the angiotensin‐converting‐enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670–1976 [DOI] [PubMed] [Google Scholar]
- 31. Dzau VJ: Angiotensin‐converting as a multimechanistic factor in CAD. J Myocard Ischemia 1995; 7: 6–14 [Google Scholar]
- 32. Young JB: Reduction of ischemic events with angiotensin‐converting enzyme inhibitors: Lessons and controversy emerging from recent clinical trials. Cardiovasc Drugs Ther 1995; 9: 89–102 [DOI] [PubMed] [Google Scholar]
- 33. Nakashima Y, Fouad FM, Tarazi RC: Regression of left ventricular hypertrophy from systemic hypertension by enalapril. Am J Cardiol 1984; 53: 1044–1049 [DOI] [PubMed] [Google Scholar]
- 34. Fennessy PA, Campbell JH, Mendelsohn FA, Campbell GR: Angiotensin‐converting enzyme inhibitors and atherosclerosis: Relevance of animal models to human disease. Clin Exp Pharmacol Physiol 1996; 23 (suppl 1): S30–S32 [DOI] [PubMed] [Google Scholar]
- 35. Thybo NK, Stephens N, Cooper A, Aalkjaer C, Heagerty AM, Mulvany MJ: Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 1995; 25 (4 Pt 1): 474–481 [DOI] [PubMed] [Google Scholar]
- 36. Furchgott RF: Role of endothelium in responses of vascular smooth muscle. Circ Res 1983; 53: 557–573 [DOI] [PubMed] [Google Scholar]
- 37. Finta KM, Fischer MJ, Lee L, Gordon D, Pitt B, Webb RC: Ramipril prevents impaired endothelium‐dependent relaxation in arteries from rabbits fed an atherogenic diet. Atherosclerosis 1993; 100: 149–156 [DOI] [PubMed] [Google Scholar]
- 38. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Luscher TF, Klibaner MI, Haber HE, Uprichard AC, Pepine CJ, Pitt B: Angiotensin‐converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996; 94: 258–265 [DOI] [PubMed] [Google Scholar]
- 39. Anderson TJ, Overhiser RW, Haber H, Charbonneau F: A comparative study of four antihypertensive agents on endothelial function in patients with coronary disease. J Am Coll Cardiol 1998; 31 (suppl): 327A [Google Scholar]
- 40. Erman A, Winkler J, Chen‐Gal B, Rabinov M, Zelykovski A, Tadjer S, Shmueli J, Levi E, Akbary A, Rosenfeld JB: Inhibition of angiotensin‐converting enzyme by ramipril in serum and tissue of man. J Hypertens 1991; 9: 1057–1062 [DOI] [PubMed] [Google Scholar]
- 41. Remme WJ: Bradykinin‐mediated cardiovascular protective actions of ACE inhibitors: A new dimension in anti‐ischaemic therapy? Drugs 1997; 54 (suppl5): 59–70 [DOI] [PubMed] [Google Scholar]
- 42. Bartels GL, van den Heuvel FM, van Veldhuisen DJ, van der Ent M, Remme WJ: Acute anti‐ischemic effects of perindoprilat in men with coronary artery disease and their relation with left ventricular function. Am J Cardiol 1999; 83: 332–336 [DOI] [PubMed] [Google Scholar]
- 43. Dzau VJ: Mechanism of protective effects of ACE inhibition on coronary artery disease. Eur Heart J 1998; 19 (suppl J): J2–J6 [PubMed] [Google Scholar]
- 44. The Heart Outcomes Prevention Evaluation Study Investigators :